Verastem (VSTM) closed at $8.38 with a mean analyst price target of $15, suggesting 79% upside potential. The stock has gained 14.5% over the past four weeks.
Analysts have revised earnings estimates higher, and VSTM holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets should not be the sole basis for investment decisions, as they are often overly optimistic.